Association of JAK2V617F mutation positivity and allele burden with posttransplant outcomes in MF, overall and by disease subtype
| JAK2 status/Allele burden (%) . | OS . | NRM . | Relapse . |
|---|---|---|---|
| HR∗ (95% CI); P . | |||
| PMF | |||
| Positive vs negative | 0.96 (0.75-1.21); .72 | 1.0 (0.75-1.34); .97 | 1.06 (0.80-1.39); .70 |
| <60% vs negative | 0.92 (0.80-1.22); .57 | 1.03 (0.73-1.44); .87 | 0.94 (0.67-1.31); .79 |
| ≥60% vs negative | 1.0 (0.76-1.31); .98 | 0.98 (0.69-1.39); .91 | 1.19 (0.86-1.65); .21 |
| Allele frequency† | 1.0 (0.99-1.00); .71 | 1.0 (0.99-1.00); .44 | 1.0 (0.99-1.01); .26 |
| PPV-MF‡ | |||
| Positive vs negative | NA | NA | NA |
| ≥90% vs <90% | 0.99 (0.56-1.73); .95 | 0.70 (0.34-1.45); .34 | 1.59 (0.82-3.09); .17 |
| Allele frequency† | 0.99 (0.98-1.00); .13 | 0.98 (0.97-1.00); .04 | 1.00 (0.99-1.02); .47 |
| PET-MF | |||
| Positive vs negative | 1.31 (0.78-2.20); .31 | 1.59 (0.76-3.35); .22 | 1.47 (0.83-2.60); .19 |
| <60% vs negative | 1.17 (0.61-2.22); .63 | 0.89 (0.34-2.31); .81 | 1.42 (0.73-2.77); .30 |
| ≥60% vs negative | 1.48 (0.78-2.82); .23 | 2.90 (1.21-6.93); .01 | 1.54 (0.72-3.30); .26 |
| Allele frequency† | 1.1 (0.99-1.02); .34 | 1.03 (1.01-1.06); .004 | 0.99 (0.98-1.01); .39 |
| JAK2 status/Allele burden (%) . | OS . | NRM . | Relapse . |
|---|---|---|---|
| HR∗ (95% CI); P . | |||
| PMF | |||
| Positive vs negative | 0.96 (0.75-1.21); .72 | 1.0 (0.75-1.34); .97 | 1.06 (0.80-1.39); .70 |
| <60% vs negative | 0.92 (0.80-1.22); .57 | 1.03 (0.73-1.44); .87 | 0.94 (0.67-1.31); .79 |
| ≥60% vs negative | 1.0 (0.76-1.31); .98 | 0.98 (0.69-1.39); .91 | 1.19 (0.86-1.65); .21 |
| Allele frequency† | 1.0 (0.99-1.00); .71 | 1.0 (0.99-1.00); .44 | 1.0 (0.99-1.01); .26 |
| PPV-MF‡ | |||
| Positive vs negative | NA | NA | NA |
| ≥90% vs <90% | 0.99 (0.56-1.73); .95 | 0.70 (0.34-1.45); .34 | 1.59 (0.82-3.09); .17 |
| Allele frequency† | 0.99 (0.98-1.00); .13 | 0.98 (0.97-1.00); .04 | 1.00 (0.99-1.02); .47 |
| PET-MF | |||
| Positive vs negative | 1.31 (0.78-2.20); .31 | 1.59 (0.76-3.35); .22 | 1.47 (0.83-2.60); .19 |
| <60% vs negative | 1.17 (0.61-2.22); .63 | 0.89 (0.34-2.31); .81 | 1.42 (0.73-2.77); .30 |
| ≥60% vs negative | 1.48 (0.78-2.82); .23 | 2.90 (1.21-6.93); .01 | 1.54 (0.72-3.30); .26 |
| Allele frequency† | 1.1 (0.99-1.02); .34 | 1.03 (1.01-1.06); .004 | 0.99 (0.98-1.01); .39 |
CMV, cytomegalovirus; GVHD, graft-versus-host disease; NA, nonapplicable
Survival models: adjusted for patient age, year of HCT, splenectomy before HCT, DIPSS, recipient-donor CMV serostatus match, donor type; NRM models: adjusted for age, CMV serostatus match, year of HCT, graft type, splenectomy, donor type, and conditioning intensity; relapse models: adjusted for splenectomy, conditioning intensity, DIPSS, GVHD prophylaxis, and stratified on year of HCT
Allele frequency is a continuous variable and tested only in patients with positive JAK2 mutation.
Mutation negative patients were excluded from this analysis because of small number (N = 4; all died in the first 12 months)